Sunlight on the Data: Why Pharma's Private Labs Are Opening Their Negative Trial Files
For decades, unfavorable clinical trial results disappeared into corporate archives, creating a distorted picture of what actually works in medicine. A convergence of regulatory pressure, institutional investor scrutiny, and competitive repositioning is now compelling major pharmaceutical and biotech firms to surface that hidden record. The consequences for scientific trust — and for the pace of genuine discovery — could be profound.